Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-ascending-dose study of Lu AF88434 in healthy young men
NL-OMON48259Phase 1Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AF88434 (3 arms), sponsored by Lundbeck. Primary endpoints: Number of participants with treatment-emergent adverse events, Cmax of Lu AF88434 and 4 more. Started Aug 2019; status: active, not recruiting.
02
Drugs
Lu AF88434
Beyond the preview
Go deeper on NL-OMON48259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48259.